In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program
Doctors are concerned with the potential harmful effects on an infants growth and feeding if GLP-1s get into the bloodstream
Healthcare providers take multiple factors into account, such as body mass index (BMI), the presence of weight-related conditions, and previous responses to promote weight loss interventions before prescribing Tirzepatide
In contrast, the longer-acting GLP-1RAs such as liraglutide and semaglutide, engineered for greater resistance to degradation, demonstrate poor penetration into the central nervous system (Salameh et al., 2020)
A qualified healthcare provider should evaluate your medical history, current medications, and metabolic markers before starting compounded tirzepatide
Gently swirl (never shake) until dissolved